eloralintide vs tirzepatide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept Triple Agonism Based Therapies for

While Mounjaro (tirzepatide) is an excellent option for many, we believe in shedding light on alternative medications, ensuring accessibility to the most fitting treatment

Key Takeaways No proof exists that tirzepatide leads to blindness

Opportunity Cost Analysis Compare semaglutide costs to alternatives: Gym membership: $30 to $100 monthly (many unused) Weight loss program subscriptions: $20 to $60 monthly (variable effectiveness) Prepared meal delivery: $200+ monthly (convenience but not addressing underlying appetite) At $199 monthly, compounded semaglutide costs approximately the same as many wellness expenses people already budget for, with significantly higher efficacy for weight loss

Continue with all routine screening tests that your healthcare provider recommends

Therefore, it will likely get full approval in 6 months (by summer of 2023) for weight loss in overweight/obese non-diabetic patients as we already have solid evidence of tackling the problem with GLP-1 receptor agonists

It should only be considered under medical supervision with appropriate monitoring